Breast cancerCA 15-3Selective Internal Radiation Therapy (SIRT)The prognosis for patients with hepatic me-tastasized breast cancer is rather poor with a median survival of 1 - 14 months and only a few patients benefit from surgical resection [1]. Selective Internal Radiation Therapy (SIRT), a...
The Role of Pre-Treatment and Mid-Treatment 18F-FDG PET/CT Imaging in Evaluating Prognosis of Peripheral T-Cell Lymphoma-Not Otherwise Specified (PTCL-NOS) The follow-ups were done to investigate the 2-year progression-free survival (PFS) and Overall Survival (OS) of these patients. During ...
Idarubicin: First-line Chemotherapy in Patients with Metastasized Breast Cancer and Favorable Prognosisdoi:10.1159/000417976H. WagnerK. PossingerP. WorstW. QueierK. BremerK. RiecheM. KleeM. WesterhausenR. Donhuijsen-AntD. Fritze
Possinger K, Wagner H, Worst P, et al. Oral administration of idaru- bicin as first line cytostatic therapy in patients with metastasized breast cancer and favourable prognosis. Onkologie 1991;14:31-4.Possinger K, Wagner H, Worst P, QueiBer W, Bremer K, Rieche K, Klee M, Wester...
Breast cancer patients with brain metastasis have a poor prognosis, with a median survival time less than 1 year despite treatment. Current chemotherapeutic agents are largely ineffective against brain metastases of breast cancer. DNA hypermethylation can lead to suppression of tumor-suppression genes ...